周三盘中，梯瓦制药（TEVA）股价大幅攀升，涨幅高达15.52%，引发市场广泛关注。这一显著涨幅主要源于公司发布的亮眼第三季度财报以及上调的全年业绩指引。
根据梯瓦制药最新发布的财务报告，公司第三季度表现出色，多项关键指标均超出市场预期。具体来看，第三季度非GAAP每股收益达到0.78美元，不仅高于去年同期的0.69美元，还大幅超越分析师预期的0.68美元。同时，季度净收入攀升至44.8亿美元，相比去年同期的43.3亿美元有所增长，同样超过了分析师预期的43.4亿美元。
除了强劲的季度业绩外，梯瓦制药还上调了2025年全年业绩展望，进一步提振了投资者信心。公司将全年非GAAP每股收益预期区间上调至2.55美元至2.65美元，高于此前2.50美元至2.65美元的预期。值得注意的是，公司维持了全年营收预期在168亿美元至170亿美元之间。这一综合表现显示梯瓦制药在当前市场环境中保持了强劲的增长势头和盈利能力，从而推动了股价的显著上涨。市场对梯瓦制药的积极表现反应热烈，导致其股价在盘中大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.